Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.91
+0.04 (0.25%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Takeda Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 4,505,720 | 4,581,550 | 4,263,760 | 4,027,480 | 3,569,010 | |
Revenue Growth (YoY) | -1.65% | 7.45% | 5.87% | 12.85% | 11.61% |
Cost of Revenue | 1,571,590 | 1,580,220 | 1,426,680 | 1,244,070 | 1,106,850 |
Gross Profit | 2,934,130 | 3,001,330 | 2,837,080 | 2,783,410 | 2,462,160 |
Selling, General & Admin | 1,084,220 | 1,104,770 | 1,053,820 | 997,309 | 886,361 |
Depreciation & Amortization Expenses | 633,544 | 643,233 | 652,117 | 542,443 | 472,915 |
Research & Development | 675,924 | 730,227 | 729,924 | 633,325 | 526,087 |
Other Operating Expenses | 131,688 | 180,521 | 187,148 | 119,823 | 115,952 |
Total Operating Expenses | 2,525,376 | 2,658,751 | 2,623,009 | 2,292,900 | 2,001,315 |
Operating Income | 408,761 | 342,586 | 214,075 | 490,505 | 460,844 |
Interest Income | 209,000 | 42,563 | 58,566 | 54,283 | 8,333 |
Interest Expense | -357,572 | -210,065 | -219,850 | -169,698 | -166,607 |
Total Non-Operating Income (Expense) | -148,572 | -167,502 | -161,284 | -115,415 | -158,274 |
Pretax Income | 260,189 | 175,084 | 52,791 | 375,090 | 302,571 |
Provision for Income Taxes | 68,163 | 66,941 | -91,406 | 58,052 | 72,405 |
Net Income | 192,026 | 108,143 | 144,197 | 317,038 | 230,166 |
Minority Interest in Earnings | 264 | 215 | 130 | 21 | 107 |
Net Income to Common | 191,762 | 107,928 | 144,067 | 317,017 | 230,059 |
Net Income Growth | 77.68% | -25.09% | -54.55% | 37.80% | -38.81% |
Shares Outstanding (Basic) | 3,150 | 3,158 | 3,129 | 3,104 | 3,127 |
Shares Outstanding (Diluted) | 3,206 | 3,211 | 3,161 | 3,140 | 3,154 |
Shares Change (YoY) | -0.16% | 1.58% | 0.67% | -0.46% | 0.23% |
EPS (Basic) | 60.88 | 34.18 | 46.05 | 102.14 | 73.57 |
EPS (Diluted) | 59.82 | 33.62 | 45.58 | 100.97 | 72.94 |
EPS Growth | 77.96% | -26.25% | -54.86% | 38.44% | -38.96% |
Free Cash Flow | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Growth | 1.06% | 58.32% | -35.34% | -16.34% | 11.13% |
Free Cash Flow Per Share | 269.98 | 266.73 | 171.14 | 266.42 | 316.98 |
Dividends Per Share | 200.000 | 196.000 | 188.000 | 180.000 | 180.000 |
Dividend Growth | 2.04% | 4.25% | 4.44% | - | - |
Gross Margin | 65.12% | 65.51% | 66.54% | 69.11% | 68.99% |
Operating Margin | 9.07% | 7.48% | 5.02% | 12.18% | 12.91% |
Profit Margin | 4.26% | 2.36% | 3.38% | 7.87% | 6.45% |
FCF Margin | 19.21% | 18.69% | 12.69% | 20.77% | 28.01% |
EBITDA | 1,129,890 | 1,103,980 | 942,077 | 1,154,910 | 1,044,000 |
EBITDA Margin | 25.08% | 24.10% | 22.10% | 28.68% | 29.25% |
EBIT | 408,761 | 342,586 | 214,075 | 490,505 | 460,844 |
EBIT Margin | 9.07% | 7.48% | 5.02% | 12.18% | 12.91% |
Effective Tax Rate | 26.20% | 38.23% | -173.15% | 15.48% | 23.93% |